Compass Therapeutics Inc.

NASDAQ CMPX

Data sourced from

and

Download Data

Compass Therapeutics Inc. Debt to Income Ratio 1 year YoY Change (%) for the quarter ending September 20, 2024

Compass Therapeutics Inc. Debt to Income Ratio 1 year YoY Change (%) is NA for the quarter ending September 20, 2024. The debt to income ratio measures the level of debt relative to a company's net income. It is calculated by dividing total debt by net income. This ratio provides insights into the company's ability to generate sufficient income to cover its debt obligations. A higher ratio indicates a higher level of debt burden relative to the company's income. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: CMPX

Compass Therapeutics Inc.

CEO	Dr. Thomas J. Schuetz M.D., Ph.D.
IPO Date	April 5, 2021
Location	United States
Headquarters	80 Guest Street, Boston, MA, United States, 02135
Employees	32
Sector	Healthcare
Industry	Biotechnology

Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Key trends